Mirroring this phenotype, ibrutinib but not acalabrutinib inhibits AICD in human T cells by reducing the upregulation of FASL, and increases CD4 and CD8 T cell numbers especially the effector/effector memory subsets in CLL patients (Long et al., 2017). The gene discussed is CD4; the disease is B-cell chronic lymphocytic leukemia.